 |
 Video: What is a Stock Split?
|
|
|
| Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Co.'s marketed product, Ocaliva® (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition, Co. is developing OCA for additional indications, including nonalcoholic steatohepatitis. According to our ICPT stock split history records, ICPT has had 0 splits. | |
|
ICPT (ICPT) has 0 splits in our ICPT stock split history database.
Looking at the ICPT stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ICPT shares, starting with a $10,000 purchase of ICPT, presented on a split-history-adjusted basis factoring in the complete ICPT stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/24/2014 |
|
| End date: |
11/08/2023 |
|
| Start price/share: |
$271.56 |
|
| End price/share: |
$19.00 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-93.00% |
|
| Average Annual Total Return: |
-24.31% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$699.95 |
|
| Years: |
9.55 |
|
|
|
|
|
